Marinus Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Marinus Pharmaceuticals, Inc.‘s stocks are currently a part of 81 hedge funds’ portfolios, which represents 81.68% of the total amount of its stocks outstanding. This makes up a total of 29.94M shares of Marinus Pharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 0.06% or 18.77K shares more. As for the holding position changes, 25.93% (21) of current hedge fund investors increased the number of shares held, 30.86% (25) of current holders sold a part of the shares held, and 12.35% (10) closed the holdings completely. 17 hedge funds are new holders of Marinus Pharmaceuticals, Inc. stock in Q1 2022, it is 20.99% of total holders.
Hedge funds holding Marinus Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 22 |
|---|---|
| Q3 2017 | 38 |
| Q4 2017 | 65 |
| Q1 2018 | 60 |
| Q2 2018 | 72 |
| Q3 2018 | 95 |
| Q4 2018 | 88 |
| Q1 2019 | 79 |
| Q2 2019 | 74 |
| Q3 2019 | 61 |
| Q4 2019 | 75 |
| Q1 2020 | 72 |
| Q2 2020 | 93 |
| Q3 2020 | 77 |
| Q4 2020 | 85 |
| Q1 2021 | 87 |
| Q2 2021 | 80 |
| Q3 2021 | 80 |
| Q4 2021 | 74 |
| Q1 2022 | 81 |
Hedge funds changes in Marinus Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 4 | 3 | 8 | 5 | 2 |
|---|---|---|---|---|---|
| Q3 2017 | 24 | 8 | 2 | 8 | -4 |
| Q4 2017 | 33 | 15 | 13 | 6 | -2 |
| Q1 2018 | 18 | 18 | 14 | 21 | -11 |
| Q2 2018 | 30 | 19 | 9 | 17 | -3 |
| Q3 2018 | 33 | 23 | 18 | 10 | 11 |
| Q4 2018 | 23 | 28 | 22 | 29 | -14 |
| Q1 2019 | 11 | 35 | 19 | 20 | -6 |
| Q2 2019 | 6 | 29 | 19 | 8 | 12 |
| Q3 2019 | 6 | 20 | 22 | 20 | -7 |
| Q4 2019 | 21 | 26 | 17 | 7 | 4 |
| Q1 2020 | 16 | 29 | 12 | 16 | -1 |
| Q2 2020 | 27 | 38 | 18 | 7 | 3 |
| Q3 2020 | 73 | 1 | 2 | 89 | -88 |
| Q4 2020 | 24 | 34 | 15 | 17 | -5 |
| Q1 2021 | 15 | 44 | 17 | 13 | -2 |
| Q2 2021 | 8 | 36 | 19 | 15 | 2 |
| Q3 2021 | 9 | 20 | 22 | 9 | 20 |
| Q4 2021 | 8 | 23 | 24 | 13 | 6 |
| Q1 2022 | 17 | 21 | 25 | 10 | 8 |
Hedge funds changes in Marinus Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 0 | 0 |
| Q4 2017 | 2,255,000 | 1,302,000 |
| Q1 2018 | 3,603,000 | 3,068,000 |
| Q2 2018 | 5,010,000 | 2,902,000 |
| Q3 2018 | 18,319,000 | 8,277,000 |
| Q4 2018 | 6,406,000 | 2,134,000 |
| Q1 2019 | 5,872,000 | 5,964,000 |
| Q2 2019 | 8,312,000 | 6,769,000 |
| Q3 2019 | 1,517,000 | 579,000 |
| Q4 2019 | 605,000 | 1,398,000 |
| Q1 2020 | 407,000 | 1,414,000 |
| Q2 2020 | 819,000 | 1,412,000 |
| Q3 2020 | 23,154,000 | 12,053,000 |
| Q4 2020 | 6,325,000 | 12,706,000 |
| Q1 2021 | 3,649,000 | 10,819,000 |
| Q2 2021 | 6,594,000 | 9,005,000 |
| Q3 2021 | 3,349,000 | 5,664,000 |
| Q4 2021 | 3,338,000 | 4,361,000 |
| Q1 2022 | 4,107,000 | 2,854,000 |